Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502.

Autor: Stover DG; Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. daniel.stover@osumc.edu.; Pelotonia Institute for ImmunoOncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. daniel.stover@osumc.edu., Salgado R; GZA-ZNA Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Savenkov O; Alliance Statistics and Data Management Center, Weill-Cornell Medical College, New York, NY, USA., Ballman K; Alliance Statistics and Data Management Center, Weill-Cornell Medical College, New York, NY, USA., Mayer EL; Dana-Farber/Partners CancerCare, Boston, MA, USA., Magbanua MJM; University of California, San Francisco, San Francisco, CA, USA., Loi S; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Vater M; Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA., Glover K; Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA., Watson M; Washington University School of Medicine, St. Louis, MO, USA., Wen Y; Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA., Symmans WF; University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Perou C; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Carey LA; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Partridge AH; Dana-Farber/Partners CancerCare, Boston, MA, USA., Rugo HS; University of California, San Francisco, San Francisco, CA, USA.
Jazyk: angličtina
Zdroj: NPJ breast cancer [NPJ Breast Cancer] 2024 Aug 21; Vol. 10 (1), pp. 75. Date of Electronic Publication: 2024 Aug 21.
DOI: 10.1038/s41523-024-00683-x
Abstrakt: Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: